Who are FluMist/B/Victoria's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FluMist Quadrivalent (2017-2018), Liquid CAIV-T, FluMist/B/Yamagata, Pandemic Influenza Vaccine, CAIV-T or TIV, Q/LAIV (MEDI3250).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flumist-b-victoria.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

FluMist/B/Victoria — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FluMist/B/Victoria (FluMist/B/Victoria) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated influenza vaccine (LAIV). Area: Immunology / Infectious Disease.

phase 3 Live attenuated influenza vaccine (LAIV) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

FluMist/B/Victoria (FluMist/B/Victoria) — MedImmune LLC. FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FluMist/B/Victoria TARGET	FluMist/B/Victoria	MedImmune LLC	phase 3	Live attenuated influenza vaccine (LAIV)
FluMist Quadrivalent (2017-2018)	FluMist Quadrivalent (2017-2018)	MedImmune LLC	marketed	Live attenuated influenza vaccine (LAIV)	Influenza virus
Liquid CAIV-T	Liquid CAIV-T	MedImmune LLC	phase 3	Live attenuated influenza vaccine (LAIV)	Influenza A and B viral surface antigens (hemagglutinin and neuraminidase)
FluMist/B/Yamagata	FluMist/B/Yamagata	MedImmune LLC	phase 3	Live attenuated influenza vaccine (LAIV)	Influenza B virus (Yamagata lineage) surface antigens
Pandemic Influenza Vaccine	Pandemic Influenza Vaccine	Altimmune, Inc.	phase 3	Live attenuated influenza vaccine (LAIV)
CAIV-T or TIV	CAIV-T or TIV	MedImmune LLC	phase 3	Live attenuated influenza vaccine (LAIV)
Q/LAIV (MEDI3250)	Q/LAIV (MEDI3250)	MedImmune LLC	phase 3	Live attenuated influenza vaccine (LAIV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated influenza vaccine (LAIV) class)

MedImmune LLC · 7 drugs in this class
Altimmune, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FluMist/B/Victoria — Competitive Intelligence Brief. https://druglandscape.com/ci/flumist-b-victoria. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab